Green Alpha Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Green Alpha Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$274K	Buy	552 +6	+1%	+$2.66K	0.18%	89
2026 Q1	$244K	Sell	546 -79	-13%	-$36.8K	0.24%	85
2025 Q4	$283K	Buy	+625	New	+$269K	0.26%	91
2025 Q3	–	Sell	-565	Closed	-$252K	–	110
2025 Q2	$252K	Sell	565 -103	-15%	-$47.5K	0.24%	89
2025 Q1	$324K	Sell	668 -21	-3%	-$9.79K	0.35%	80
2024 Q4	$277K	Sell	689 -129	-16%	-$59.8K	0.22%	117
2024 Q3	$380K	Sell	818 -69	-8%	-$33.1K	0.3%	102
2024 Q2	$416K	Sell	887 -118	-12%	-$51.2K	0.33%	98
2024 Q1	$420K	Sell	1,005 -8	-0.8%	-$3.38K	0.3%	108
2023 Q4	$412K	Sell	1,013 -179	-15%	-$66.1K	0.3%	117
2023 Q3	$415K	Sell	1,192 -651	-35%	-$228K	0.32%	106
2023 Q2	$649K	Buy	1,843 +252	+16%	+$84.9K	0.43%	88
2023 Q1	$501K	Sell	1,591 -45	-3%	-$13.5K	0.35%	105
2022 Q4	$472K	Sell	1,636 -16	-1%	-$4.88K	0.39%	104
2022 Q3	$478K	Buy	1,652 +6	+0.4%	+$1.73K	0.4%	111
2022 Q2	$464K	Sell	1,646 -1,189	-42%	-$318K	0.11%	129
2022 Q1	$740K	Buy	2,835 +109	+4%	+$25.9K	0.5%	83
2021 Q4	$599K	Buy	2,726 +63	+2%	+$12.3K	0.4%	100
2021 Q3	$483K	Buy	2,663 +265	+11%	+$51.7K	0.33%	118
2021 Q2	$484K	Buy	2,398 +479	+25%	+$100K	0.33%	120
2021 Q1	$412K	Buy	+1,919	New	+$422K	0.41%	89

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Green Alpha Advisors's VRTX Position: Q2 2026 in Review

Green Alpha Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 1.1% in Q2 2026, buying an estimated $2.66K and bringing the position to 552 shares worth $274K. The position accounts for 0.18% of the portfolio, ranked #89.

Green Alpha Advisors first reported a position in VRTX in Q1 2021 and has held it in 21 quarters since. The position peaked at $740K in Q1 2022. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Green Alpha Advisors held 552 shares of Vertex Pharmaceuticals worth $274K as of Q2 2026.
Green Alpha Advisors bought 6 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.66K.
Vertex Pharmaceuticals made up 0.18% of Green Alpha Advisors's portfolio in Q2 2026, its #89 holding.
Green Alpha Advisors first reported a position in Vertex Pharmaceuticals in Q1 2021 and has held it in 21 quarters since.
Green Alpha Advisors's Vertex Pharmaceuticals position peaked at $740K in Q1 2022.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Green Alpha Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.